Lower plasma adiponectin levels have been shown to be associated with insulin resistance, type 2 diabetes, and proatherogenic dyslipidemia as well as with an increase in the level of proinflammatory markers and endothelium disorders. Here, ADIPOQ is linked to metabolic syndrome.